Brainstorm Cell Therapeutics Inc. (OTCQB: BCLI) reported a full‑year 2025 net loss of $10.3 million, a slight improvement from the $11.6 million loss recorded in 2024. Operating expenses totaled $9.95 million, driven by $4.2 million in research and development and $5.8 million in general and administrative costs. The company’s cash and cash equivalents at December 31 2025 were approximately $300,000, down from roughly $1.45 million at the end of 2023, underscoring a burn rate of about $10 million per year.
The modest $2 million strategic financing secured in February 2026 has extended Brainstorm’s runway, but the cash balance remains insufficient to cover the estimated $20‑30 million annual cost required to complete the Phase 3b ENDURANCE trial of its NurOwn therapy. With a year‑end cash balance of only $300,000, the company faces a high risk of liquidity shortfall unless additional capital is raised.
Brainstorm’s NurOwn program has faced significant regulatory hurdles. After a Refusal to File letter in November 2022 and a negative Advisory Committee vote in September 2023, the company withdrew its BLA. In 2025, the FDA cleared the planned Phase 3b confirmatory study, a critical milestone that could pave the way for a future BLA submission.
CEO Chaim Lebovits emphasized the strategic importance of the Phase 3b trial, stating, "Our main priority continues to be advancing NurOwn into a Phase 3b confirmatory study, having received clearance from the FDA in 2025 for the planned study." He added, "Further, we believe that the $2.0 million in strategic financing secured in early 2026 has served as the catalyst for our recovery, resulting in a significant re‑rating of our shares and providing the cash runway to execute on key operational activities."
The company’s financial position remains precarious. While the $2 million financing provides a temporary cushion, the ongoing need for capital to fund the Phase 3b trial and the absence of revenue mean that Brainstorm must secure additional funding to avoid a potential insolvency scenario. The company’s management signals confidence in the trial’s potential, but the high cost and regulatory uncertainty continue to pose significant risks to its long‑term viability.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.